Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
BEIGENE, LTD. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 186.94 USD | +2.08% | +2.27% | -15.00% | |
| Nov. 21 | BeiGene Acquires Global License for CDK2 Inhibitor From Ensem Therapeutics | MT |
| Nov. 21 | BeiGene to buy global rights to Ensem's experimental cancer therapy | RE |
Financials (USD)
| Sales 2023 * | 2,412 M | Sales 2024 * | 3,030 M | Capitalization | 19.06 B |
|---|---|---|---|---|---|
| Net income 2023 * | -907 M | Net income 2024 * | -840 M | EV / Sales 2023 * | 6,65x |
| Net cash position 2023 * | 3,027 M | Net cash position 2024 * | 1,748 M | EV / Sales 2024 * | 5,72x |
| P/E ratio 2023 * | -24,1x | P/E ratio 2024 * | -24,4x | Employees | 10,000 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.73% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.08% | ||
| 1 week | +2.27% | ||
| Current month | +0.35% | ||
| 1 month | +9.67% | ||
| 3 months | -12.48% | ||
| 6 months | -21.09% | ||
| Current year | -15.00% |
1 week
180.94
189.15
1 month
178.78205.40
Current year
156.56280.62
1 year
156.56280.62
3 years
118.18426.56
5 years
108.00426.56
10 years
22.51426.56
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.39% | 396 M€ | -5.03% | ||
| 3.03% | 27 M€ | -15.98% | - | |
| 3.00% | 4 M€ | -.--% | - | |
| 2.48% | 4 M€ | -27.92% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-11-30 | 186.94 | +2.08% | 186,819 |
| 23-11-29 | 183.13 | -0.93% | 187,468 |
| 23-11-28 | 184.84 | +1.03% | 104,101 |
| 23-11-27 | 182.96 | -0.95% | 145,570 |
| 23-11-24 | 184.72 | +1.05% | 183,480 |
Delayed Quote Nasdaq, November 30, 2023 at 04:00 pm EST
More quotes
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in licensed the rights to distribute 13 approved medicines for the China market. BRUKINSA is a second-generation small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects.
Calendar
2023-12-08
- BeiGene Cancer and Mental Health Forum
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
186.94USD
Average target price
285.19USD
Spread / Average Target
+52.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.00% | 19 064 M $ | |
| +22.87% | 90 447 M $ | |
| +14.18% | 85 991 M $ | |
| +1.98% | 34 975 M $ | |
| +16.97% | 26 060 M $ | |
| -33.16% | 23 593 M $ | |
| -26.52% | 20 576 M $ | |
| -2.42% | 11 156 M $ | |
| +21.83% | 10 875 M $ | |
| -37.27% | 7 521 M $ |
